• Biomea Fusion posted a net loss attributable to common stockholders of USD 8.3 million, narrowing from USD 20.7 million a year earlier.
• R&D expense fell to USD 9.1 million from USD 16.6 million, on lower external, personnel, manufacturing, and facilities-related costs.
• G&A expense declined to USD 3.6 million from USD 4.7 million, driven mainly by lower personnel-related costs on reduced headcount.
• Cash, cash equivalents and restricted cash totaled USD 35.2 million at June 30, 2026; cash runway projected into the second quarter of 2027.
• COVALENT-211 Phase II data expected in Q1 2027; COVALENT-212 data expected in Q2 2027; initial 28-day BMF-650 weight-loss data due Q3 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomea Fusion Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608051605PRIMZONEFULLFEED9803827) on August 05, 2026, and is solely responsible for the information contained therein.